Adjuvant Chemotherapy and Immunotherapy

Temozolomide-cisplatin improved relapse-free and overall survival compared with observation and high-dose interferon in a randomized phase II trial. Pembrolizumab plus temozolomide showed better progression-free survival than temozolomide-based chemotherapy alone in advanced melanoma retrospective data. The trial regimen uses pucotenlimab, temozolomide, and cisplatin for six 3-week systemic therapy cycles. Chinese randomized phase II data support adjuvant temozolomide plus cisplatin after resection of mucosal melanoma. Chemotherapy is presented as a rational backbone for combination with PD-1 inhibition.